| |
|
|
|
Drug Information Association, Online
Mar 28 2008
Many public health experts believe that the threat of an avian influenza pandemic is one of the most pressing health issues facing the world today. A pandemic, which has the potential to disrupt social, political, and economic structures, could have dramatic impact on the pharmaceutical industry’s ability to produce and distribute the life-sustaining drugs that millions of patients rely on every day. Despite the efforts of the private and public sectors, there remains considerable work to be done. And the pharmaceutical industry, in particular, will be expected to stay operational during this time of crisis. Join experts from the business and pandemic planning community and the pharmaceutical industry to discuss:·Why pandemic influenza is a threat to your company,·How a pandemic plan differs from a generic disaster or business continuity plan,·Best practices in pandemic planning for the pharmaceutical industry,·What you and your organization should be doing today to ready your business for pandemic influenza.
|
|
|
|
|
|
|
|
Organized by:
|
|
Drug Information Association |
|
|
Invited Speakers:
|
|
1) Alex A. NawotkaDirector, Corporate Pandemic readinessRoche LaboratoriesUnited States. 2) John McFadden, JDDirector of Business Continuity and Crisis PlanningGenzyme CorporationUnited States. 3) Stuart B. Weiss, MDCEOMedPrep Healthcare Consultants, LLCUnited States.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
-
|
|
|
|
|
|
|
|
Registration:
|
|
http://www.diahome.org/DIAHOME/Education/FindEducationalOffering.aspx?productID=16709&eventType=Webinar
|
|
|
E-mail:
|
|
dia@diahome.org
|
|
|
|
|
|
|
|
|